Insights Into the Burden and Unmet Needs of Patients With Hereditary Angioedema: A Retrospective Social Media Listening Study

Julia Braverman¹, Quazi Ataher¹, Darcy Ellis¹, Simona Gavata-Steiger¹, Angeline Babitha², Revanth Muthu²

¹CSL Behring, King of Prussia, PA, USA; ²CapeStart Inc., Cambridge, MA, USA.



CONCLUSIONS

- Despite the availability of treatments for hereditary angioedema (HAE), unmet needs still exist and patients living with HAE experience substantial disease burden
- Real-life experiences gathered via social media can support HAE management optimization

BACKGROUND

- HAE is a rare genetic disorder that causes recurrent, unpredictable, debilitating, and potentially life-threatening angioedema attacks, which substantially impair quality of life¹⁻³
- Despite the availability of modern HAE treatments, patients continue to experience a high burden of disease and have unmet needs⁴
- Understanding the experiences of patients living with HAE and the patient journey is critical for optimizing HAE management
- Social media platforms provide outlets for patient communities to freely find, exchange, and discuss health information⁵⁻⁷ and are therefore recognized as a valuable method used to capture the patient voice and better understand patients' lived experiences and unmet needs

OBJECTIVE



• This social media listening study was conducted to identify and characterize the experiences, burdens, and unmet needs of patients living with HAE

METHODS: RETROSPECTIVE SOCIAL MEDIA LISTENING STUDY



Determine search strategy

Iterative, keyword-based search:

- Predefined search terms
- English language keywords
- Data collection range: Jan 2018-Oct 2023

Manual data

collection

- X (formerly known as Twitter)
- Reddit
- Social media platforms used: Quora
 - YouTube Patient forums
- Facebook

Data screening

Subject matter experts:

and extraction

- Remove duplicates
- Anonymize data
- Determine relevancy
- Extract and categorize according to themes

In-depth


data analysis **Quantitative and**

qualitative analysis:

• By identified subcategory topics and themes

RESULTS: DISEASE BURDEN AND TREATMENT NEEDS WERE COMMON TOPICS

- HAE topics considered relevant for the analysis included burdens,* unmet needs,* medications, symptoms, triggers, side effects, and misdiagnoses
- Posts discussing disease awareness, news, studies, or other diseases and were excluded from the analysis




86% of posts were written by patients, 10% by family/friends

57% of posts were published in **2023**, 15% in 2022

56% of posts originated from Facebook, 22% from X (Twitter)

*Predetermined theme of interest; †All posts were available in the public domain.



The most commonly discussed unmet need was treatment need Unmet needs topic, by number of posts (total 270/892 posts)* **20 2**269 **2**69 123 6 971 Treatment 85 🕩 117 **1**4 **9**73 Educational **1**5 **2**146 **2**146 69 167 Health service Likes Shares **1**44 **1**10 **2**21 42 Diagnostic Reactions 100 120 20 80 140 Number of posts Common themes discussed in treatment needs posts: Treatment needs data: • Insurance denials • 123 posts Unavailability of medications • 971 likes High treatment costs • 20 shares Questions about alternative treatments • 269 reactions • Uncertainty about where to find the right medications

*A single post may discuss more than one topic; †Injection burden related to the process of administration of treatment, whereas medication burden related to the intricacy of controlling HAE symptoms and adverse experiences with medication. HAE, hereditary angioedema; QoL, quality of life.

*A single post may discuss more than one topic.

Quotes from patients online






"I learned to navigate life with painful, disfiguring swelling"



"I can't eat anymore because it became too painful"



"The hospital told me not to come back because they didn't know what to do for me"

"I'm scared they [employers] won't hire me officially unless they find a way to cover some of the cost"

1. Craig TJ et al. Lancet 2023;401:1079–1090; 2. Bork K et al. Allergy Asthma Clin Immunol 2021;17:40; 3. Maurer M et al. Allergy 2022;77:1961–1990; 4. Banerji A et al. Ann Allergy Asthma 2020;124:600-607; 5. Kline E et al. Health Expectations 2023;26:1524-1535; 6. Faust G et al. JMIR Cancer 2022;8:e34073; 7. Peric Z et al. JMIR Cancer 2023;9:e42905.

This study was sponsored by CSL Behring. Medical writing support was provided by Suzanne Berresford, BPharm, of Helix, OPEN Health Communications, and funded by CSL Behring, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).